FINWIRES · TerminalLIVE
FINWIRES

PYC Therapeutics Says ADOA Patients Show Sustained Visual Acuity, Retinal Stress Improvements in Drug Candidate Trials

By

PYC Therapeutics (ASX:PYC) said autosomal dominant optic atrophy (ADOA) patients in the ongoing clinical trials of its PYC-001 drug candidate showed sustained improvement in both visual acuity and retinal stress following repeat doses, according to a Tuesday Australian bourse filing.

Non-human primates treated with a single dose of the candidate at 15 micrograms per eye showed a sustained increase in OPA1 protein target gene expression in the retina four months after a single treatment.

Human patients are currently receiving the candidate once every two to three months. The data from non-human primates support extending the dosing interval to once every four months or more. The firm plans to review the clinical protocol for the ongoing studies with a view to extending the dosing interval in these trials.

Related Articles

Asia

Eoptolink Expects H1 Profit to Rise by Up to 103%; Shares Up 4%

Eoptolink Technology (SHE:300502) expects its net profit attributable to shareholders in the first half to jump by between 78% and 103% year on year to a range of 7 billion yuan to 8 billion yuan, according to a Shenzhen bourse filing on Monday.The attributable profit a year earlier was 3.94 billion yuan.The company attributed the forecast to an increase in revenue due to the growth in investment in artificial intelligence-related computing power. The non-recurring gains and losses will also increase net profit by approximately 19 million yuan.The optical transceiver module manufacturer's shares rose 4% during the morning trade.

SHE:300502
Asia

Malaysia Pension Fund Pursuing Recovery of eFishery Investment After Fraud Case

Malaysia's state pension fund Kumpulan Wang Persaraan (KWAP) said it invested 163.4 million ringgit in Indonesian agritech startup eFishery for a 2.51% minority stake and is pursuing "all available avenues to maximize recovery of the investment."The statement followed a Bloomberg report that Malaysia's anti-graft agency had launched an investigation into losses linked to KWAP's investment in eFishery.KWAP said the losses stemmed from deliberate financial manipulation at eFishery. The fund noted that co-founder and former Chief Executive Officer Gibran Huzaifah was sentenced to nine years in prison in April for embezzlement and money laundering.The pension fund said it has completed an internal review of the investment and strengthened its private market investment process and portfolio monitoring after the irregularities were uncovered.

FTSE Bursa Malaysia KLCI
Asia

Medi Lifestyle Appoints CEO; Shares Up 4%

Medi Lifestyle (SGX:Z4D) has appointed Tan Lee Seng as chief executive officer, with effect from Friday, according to a same-day filing to the Singapore bourse.Prior to the appointment, Seng was an executive director of the company.His responsibilities include the overall management and execution of the group's strategic objectives, including overseeing business development, driving corporate growth and expansion initiatives, and leading the group's performance and corporate planning activities.The company's shares were up nearly 4% in Monday's trade.

SGX:Z4D